A foot in the door

Paul, Reld
September 2008
Pharmaceutical Representative;Sep2008, Vol. 38 Issue 9, p3
The author reflects on the revised PhRMA code for the pharmaceutical industry in the U.S. He states that the code is one of the most visible steps that the pharmaceutical industry has taken in some time to improve reputation. He adds that critics are quick to point out that the voluntary rules are chock full of loopholes that allow individual pharmaceutical representatives or companies to continue business as usual. He says that it will be the doctors who determine the impact of the code.


Related Articles

  • What! No Pens?! Berliner, Neil // Pharmaceutical Representative;Sep2008, Vol. 38 Issue 9, p31 

    The author reflects on the PhRMA code in the pharmaceutical industry in the U.S. He states that PhRMA chief executive officer Billy Tauzin hopes that the code additions will create more credible standards for doctor-sales representative interactions. He comments on the statement from PhRMA that...

  • WHAT FINANCIAL SERVICES NEEDS TO LEARN FROM PHARMA.  // Financial & Insurance Meetings;Jul/Aug2008, Vol. 44 Issue 4, p34 

    The article deals with the lessons the financial services industry needs to learn from the crisis faced by the U.S. pharmaceutical industry in 2002. The pharmaceutical industry was widely vilified for providing doctors free meals, entertainment and travel. In response, the Pharmaceutical...

  • MA Senate proposes outright gift ban. McGuire, Stephen // Medical Marketing & Media;Apr2008, Vol. 43 Issue 4, p22 

    The article reports on the gift ban legislation proposed by Massachusetts State Senate Leader, Therese Murray. The proposal prohibits pharmaceutical companies from giving all sorts of gifts to doctors or to physicians' families and employees. The Pharmaceutical Research and Manufacturers of...

  • With Our Dollars for Docs Update Coming, Drug Companies Defend 'Interactions' With Physicians - ProPublica. Ornstein, Charles; Weber, Tracy // Pro Publica;9/6/2011, p15 

    The article announces that ProPublica, a non-profit, will be posting an update to its Dollars for Docs database, adding new payment reports from 12 drug companies that comprise more than 40 percent of U.S. drug sales. It mentions that the Pharmaceutical Research and Manufacturers of America...

  • The Changing Industry-Practitioner Relationship. Sussman, Norman // Primary Psychiatry;Dec2008, Vol. 15 Issue 12, p22 

    Generations of physicians have been accustomed to receiving pens, pads, mugs, and assorted models of the spine, the brain, and other organs, all courtesy of pharmaceutical and medical device manufacturers. Most, if not all, of these gifts will cease as of January 2009, when a new guideline for...

  • The Pharmaceutical Research and Manufacturers of America (PhRMA), Amicus Curiae. Calia, Kurt G. // Supreme Court Debates;Sep2013, Vol. 16 Issue 6, p28 

    An excerpt from the Amicus Curiae Brief for Respondents that was submitted to the U.S. Supreme Court in March 2013, involving the Pharmaceutical Research and Manufacturers of America (PhRMA), is presented.

  • Building a Healthcare System. Tauzin, Billy // Vital Speeches of the Day;4/1/2006, Vol. 72 Issue 12, p378 

    This article presents a speech given by Billy Tauzin, president and CEO of PhRMA, delivered to the 2006 Annual Membership Meeting, at the American Tort Reform Association, in Washington, D.C., on March 22, 2006. Tauzin discusses how the PhRMA's safety record and how the pharmaceutical industry...

  • Robust Cancer Pipeline.  // Pharmaceutical Representative;May2011, Vol. 41 Issue 5, p8 

    The article accounts on the report released by the Pharmaceutical Research and Manufacturers of America (PhRMA) regarding the 900 therapies for the treatment, prevention, or diagnosis of cancer that are currently in development, which is more than double the number of therapies six years ago.

  • Docs Find Value in What You Say.  // Pharmaceutical Representative;May2011, Vol. 41 Issue 5, p12 

    The article presents the findings of a survey commissioned by the Pharmaceutical Research and Manufacturers of America, in which it shows that 69 percent of the 508 physicians use information from pharmaceutical sales representatives and company when determining which medication to prescribe.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics